Clinical trial · Observational
Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT
Prognosis of Patients With Relapsed/Refractory Hl Treated With Combination of Ifosfamide, Gemcitabine and Vinorelbine(IGEV) Induction Therapy Before High-dose Chemotherapy (HDCT) With Autologous Hematopoietic Stem Cells Transplantation (AHSCT)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify a prognostic score with clinical and therapeutic relevance by using 6 clinical tools: 1. B symptoms(yes/no) 2. relapse in previously irradiated areas(yes/no) 3. Ann Arbor Stage (III/IV vs I/II) 4. disease status at accrual (refractory vs relapsed) 5. Early relapse within 12 months of Complete Response (CR) versus late relapse after Complete Response (CR) lasting \> l2 months", 6. extranodal involvement (yes/no).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The prognostic score will be defined taking into account Overall Survival (OS).
- timeFrame
- 4 years
- description
- Surviving patents will be censored at the date of last known to be alive.
Secondary outcomes (1)
- measure
- To evaluate the defined prognostic score in terms of Progression Free Survival (PFS)
- timeFrame
- 4 years
- description
- response rate in terms of Complete Response (CR) response rate in terms of Overall Response Rate (ORR) To validate the prognostic scores in terms of PFS and in terms OS
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT * Age \>18 years * Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR. Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion). * Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up * Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen. * First IGEV course started before December 31st 2007 * Assessment of tumor response by Cheson 1999 criteria 11 Exclusion Criteria: * NONE
References
Publications (0)
Data not yet available